Market Overview

Protalix Says Reviewing Partnering, Other Alternatives

Related PLX
Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease
Morning Market Gainers

Protalix BioTherapeutics, Inc. (NYSE: PLX) confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative.

Protalix will not comment further on this initiative unless future events would make doing so appropriate.

Posted-In: News


Related Articles (PLX)

Get Benzinga's Newsletters